Comparison Chart Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 21:00:00 16/01/2026 GMT			5-day change	1st Jan Change
1.810 ^USD	+2.84%		-9.50%	+21.48%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Total Return

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes

Compared values

		Sector	Change	5d. change	Varia. Jan 1.	1-year change	5-years change	Capi.	ST	MT	LT
	MARKER THERAPEUTICS, INC.	Other Biotechnology & Medical Research	+2.84%	-9.50%	+21.48%	-26.42%	-91.26%	30.18M